Autism Spectrum Disorder and Aripiprazole

Paper Summary

Autism Spectrum Disorder (ASD) often involves behavioral and psychological challenges that can limit a person’s ability to function socially and emotionally. This study explores the use of aripiprazole, an FDA-approved antipsychotic, as a primary treatment for ASD. In six case studies involving patients aged 23 months to 29 years, aripiprazole effectively reduced core symptoms such as aggression, irritability, and social withdrawal with minimal side effects. The research suggests that aripiprazole works quickly and is especially helpful for individuals with hypersensitivity. Unlike previous medications like risperidone, aripiprazole showed more consistent success in improving patients' overall quality of life. The study argues that medication should come before behavioral therapy to first stabilize symptoms, making it easier for patients to benefit from social skills programs like Applied Behavioral Analysis. Ultimately, early and consistent use of aripiprazole can help individuals with ASD build the foundation needed to lead healthier and more socially connected lives.